Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 14/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 9/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 8/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.36 |
| ▸ | RORA | P35398 | 1/20 | 0.36 |
| ▸ | RORB | Q92753 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626253 | 0.92 | BCHE (0.37) | RORCNR1H3NR1H2NR1I2RORA | |
| SCHEMBL3626249 | 0.92 | BCHE (0.37) | RORCNR1H3NR1H2NR1I2RORA | |
| SCHEMBL13317202 | 0.92 | BCHE (0.37) | RORCNR1H3NR1H2NR1I2RORA | |
| SCHEMBL3623596 | 0.92 | BCHE (0.37) | RORCNR1H3NR1H2NR1I2RORA | |
| SCHEMBL3623599 | 0.92 | BCHE (0.37) | RORCNR1H3NR1H2NR1I2RORA | |
| SCHEMBL3627829 | 0.84 | RORC (0.43) | RORCNR1H3NR1H2NR1I2MLYCD | |
| SCHEMBL12023928 | 0.84 | RORC (0.43) | RORCNR1H3NR1H2NR1I2MLYCD | |
| SCHEMBL3626859 | 0.79 | RORC (0.44) | RORCNR1H3NR1H2NR1I2RORA | |
| SCHEMBL3624600 | 0.78 | RORC (0.46) | RORCNR1H3NR1H2NR1I2 | |
| SCHEMBL12024161 | 0.74 | NR1H3 (0.39) | RORCNR1H3NR1H2NR1I2RORA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2392567-B1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2392567-A1 | BENZOTHIAZINE DERIVATIVES AND THEIR USE AS LXR MODULATORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741317-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
| US-20070093470-A1 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093470-A1 | LXR modulators | NR1H2, NR1H3, RXRB | RORC 66/4885NR1H3 2/4885NR1H2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.